Progesterone antagonists and progesterone receptor modulators: An overview

Steroids

Volumn 68, Issue 10-13, 2003, Pages 981-993

  Spitz, Irving M ^a,b  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

^b POPULATION COUNCIL   (United States)

Author keywords

Antiglucocorticoid; Clinical applications; Cushing's syndrome; Endometriosis; Mifepristone; Myoma; PAs; Pregnancy termination; PRMs; SPRMs

Indexed keywords

ANTIGESTAGEN; ESTRADIOL; LUTEINIZING HORMONE; MIFEPRISTONE; MISOPROSTOL; ONAPRISTONE; POSTCOITUS CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR MODULATOR; PROSTAGLANDIN;

ALOPECIA; ANOREXIA; BREAST CANCER; CELL MATURATION; CELL PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; CUSHING DISEASE; DOSE RESPONSE; DRUG ERUPTION; DRUG SAFETY; ENDOMETRIAL DISEASE; ENDOMETRIOSIS; ENDOMETRIUM; ESTRADIOL BLOOD LEVEL; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FATIGUE; FERTILIZATION IN VITRO; FETUS DEATH; FIRST TRIMESTER PREGNANCY; FOLLICULAR PHASE; GESTATIONAL AGE; GYNECOMASTIA; HORMONAL CONTRACEPTION; HORMONAL THERAPY; HORMONE INHIBITION; HOT FLUSH; HUMAN; HYPOTHYROIDISM; LIBIDO DISORDER; LIVER TOXICITY; MENINGIOMA; MENOPAUSAL SYNDROME; MENSTRUATION DISORDER; METRORRHAGIA; MYOMA; NAUSEA; NONHUMAN; OSTEOLYSIS; OVULATION; PREGNANCY TERMINATION; RASH; SEPTIC SHOCK; SIDE EFFECT; SKELETON MALFORMATION; TREATMENT WITHDRAWAL; UTERUS; UTERUS RUPTURE; VOMITING; WEIGHT REDUCTION;

EID: 0142205817     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2003.08.007     Document Type: Conference Paper

References (152)

1. Philibert D, Deraedt R, Teutsch G. RU 38486: a potent antiglucocorticoid in vivo. In: Proceedings of the VII International Congress of Pharmacology, Tokyo, Japan; 1981.
2. Spitz I.M., Croxatto H.B., Robbins A. Antiprogestins: mechanism of action and contraceptive potential. Annu. Rev. Pharmacol. Toxicol. 36:1996;47-81.
3. Wagner B.L., Norris J.D., Knotts T.A., Weigel N.L., McDonnell D.P. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol. Cell Biol. 18:1998;1369-1378.
4. Liu Z., Auboeuf D., Wong J., Chen J.D., Tsai S.Y., Tsai M.J.et al. Coactivator/corepressor ratios modulate PR-mediated transcription by the selective receptor modulator RU486. Proc. Natl. Acad. Sci. U.S.A. 99:2002;7940-7944.
5. Leonhardt S.A., Edwards D.P. Mechanism of action of progesterone antagonists. Exp. Biol. Med. (Maywood). 227:2002;969-980.
6. Giangrande P.H., McDonnell D.P. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog. Horm. Res. 54:1999;291-313. ; discussion 313-4.
7. Spitz I.M., Chwalisz K. Progesterone receptor modulators and progesterone antagonists in women's health. Steroids. 65:2000;807-815.
8. Spitz I.M. Preface. Steroids. 65:2000;543-544.
9. Elger W., Bartley J., Schneider B., Kaufmann G., Schubert G., Chwalisz K. Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity. Steroids. 65:2000;713-723.
10. Klein Hitpass L., Cato A.C., Henderson D., Ryffel G.U. Two types of antiprogestins identified by their differential action in transcriptionally active extracts from T47D cells. Nucleic Acids Res. 19:1991;1227-1234.
11. Gass E.K., Leonhardt S.A., Nordeen S.K., Edwards D.P. The antagonists RU486 and ZK98299 stimulate progesterone receptor binding to deoxyribonucleic acid in vitro and in vivo, but have distinct effects on receptor conformation. Endocrinology. 139:1998;1905-1919.
12. Onate S.A., Tsai S.Y., Tsai M.J., O'Malley B.W. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science. 270:1995;1354-1357.
13. McPhail M.K. J. Physiol. 83:1934;145-156.
14. Philibert D. RU38486: an original multifaceted antihormone in vivo. In: Agarwal M, editor. Adrenal steroid antagonism. Berlin: Walter de Gruyter and Co.; 1984. p. 77-101.
15. Fuhrmann U., Hess Stumpp H., Cleve A., Neef G., Schwede W., Hoffmann J. et al. Synthesis and biological activity of a novel, highly potent progesterone receptor antagonist. J. Med. Chem. 43:2000;5010-5016.
16. Sartorius C.A., Tung L., Takimoto G.S., Horwitz K.B. Antagonist-occupied human progesterone receptors bound to DNA are functionally switched to transcriptional agonists by cAMP. J. Biol. Chem. 268:1993;9262-9266.
17. Beck C.A., Weigel N.L., Moyer M.L., Nordeen S.K., Edwards D.P. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc. Natl. Acad. Sci. U.S.A. 90:1993;4441-4445.
18. Wagner B.L., Pollio G., Leonhardt S., Wani M.C., Lee D.Y., Imhof M.O.et al. 16-Alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. Proc. Natl. Acad. Sci. U.S.A. 93:1996;8739-8744.
19. World Health Organisation task force on postovulatory methods of fertility regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ 1993;307:532-7.
20. Christin-Maitre S., Bouchard P., Spitz I.M. Medical termination of pregnancy. New Engl. J. Med. 342:2000;946-956.
21. Creinin M.D., Pymar H.C., Schwartz J.L. Mifepristone 100 mg in abortion regimens. Obstet. Gynecol. 98:2001;434-439.
22. World Health Organization task force on postovulatory methods for fertility regulation. Lowering the doses of mifepristone and gameprost for early abortion: a randomised controlled trial. BJOG 2001;108:738-42.
23. Prasad R.N., Choolani M. Termination of early human pregnancy with either 50 mg or 200 mg single oral dose of mifepristone (RU486) in combination with either 0.5 mg or 1.0 mg vaginal gemeprost. Aust. NZJ Obstet. Gynaecol. 36:1996;20-23.
24. Zieman M., Fong S.K., Benowitz N.L., Banskter D., Darney P.D. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet. Gynecol. 90:1997;88-92.
25. Aubeny E., Chatellier G. A randomized comparison of mifepristone and self-administered oral or vaginal misoprostol for early abortion. Eur. J. Contracept. Reprod. Health Care. 5:2000;171-176.
26. Schaff E.A., Fielding S.L., Westhoff C. Randomized trial of oral versus vaginal misoprostol at one day after mifepristone for early medical abortion. Contraception. 64:2001;81-85.
27. Tang O.S., Xu J., Cheng L., Lee S.W., Ho P.C. Pilot study on the use of sublingual misoprostol with mifepristone in termination of first trimester pregnancy up to 9 weeks gestation. Hum. Reprod. 17:2002;1738-1740.
28. Wagaarachchi P.T., Ashok P.W., Smith N.C., Templeton A. Medical management of early fetal demise using sublingual misoprostol. BJOG. 109:2002;462-465.
29. Schaff E.A., Fielding S.L., Westhoff C., Ellertson C., Eisinger S.H., Stadalius L.S.et al. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA. 284:2000;1948-1953.
30. Creinin M.D., Schwartz J.L., Pymar H.C., Fink W. Efficacy of mifepristone followed on the same day by misoprostol for early termination of pregnancy: report of a randomised trial. BJOG. 108:2001;469-473.
31. Jain J.K., Dutton C., Harwood B., Meckstroth K.R., Mishell D.R. Jr. A prospective randomized, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Hum. Reprod. 17:2002;1477-1482.
32. Schaff E., Eisinger S., Stadalius L., Franks P., Gore B., Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for abortion. Contraception. 59:1999;1-6.
33. Bartley J., Brown A., Elton R., Baird D.T. Double-blind randomized trial of mifepristone in combination with vaginal gemeprost or misoprostol for induction of abortion up to 63 days gestation. Hum. Reprod. 16:2001;2098-2102.
34. Spitz I.M., Bardin C.W., Benton L., Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N. Engl. J. Med. 338:1998;1241-1247.
35. Aubeny E., Peyron R., Larquier Turpin C., Renault M., Targosz V., Silvestre L.et al. Termination of early pregnancy (up to 63 days of amenorrhea) with mifepristone and increasing doses of misoprostol. Int. J. Fertil. 40(Suppl 2):1995;85-91.
36. Ashok P.W., Penney G.C., Flett G.M., Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum. Reprod. 13:1998;2962-2965.
37. El-Rafeay H., Rajasekar D., Abdalla M., Calder L., Templeton A. Induction of abortion with mifepristone (RU486) and oral or vaginal misoprostol. N. Engl. J. Med. 332:1995;983-987.
38. Baird D.T., Sukcharoen N., Thong K.J. Randomized trial of misoprostol and cervagem in combination with a reduced dose of mifepristone for induction of abortion. Hum. Reprod. 10:1995;1521-1527.
39. Urquhart D., Templeton A., Shinwei F., Chapman M., Hawkins K., McGarry J.et al. The efficacy and tolerance of mifepristone and prostaglandin in termination of pregnancy of less than 63 days gestation, UK multicentre study: final results. Contraception. 55:1997;1-5.
40. Ashok P.W., Templeton A., Wagaarachchi P.T., Flett G.M. Factors affecting the outcome of early medical abortion: a review of 4132 consecutive cases. BJOG. 109:2002;1281-1289.
41. Child T.J., Thomas J., Rees M., MacKenzie I.Z. A comparative study of surgical and medical procedures: 932 pregnancy terminations up to 63 days gestation. Hum. Reprod. 16:2001;67-71.
42. Bartley J., Tong S., Everington D., Baird D.T. Parity is a major determinant of success rate in medical abortion: a retrospective analysis of 3161 consecutive cases of early medical abortion treated with reduced doses of mifepristone and vaginal gemeprost. Contraception. 62:2000;297-303.
43. Bartley J., Baird D.T. A randomised study of misoprostol and gemeprost in combination with mifepristone for induction of abortion in the second trimester of pregnancy. BJOG. 109:2002;1290-1294.
44. Ashok P.W., Templeton A. Non-surgical mid-trimester termination of pregnancy: a review of 500 consecutive cases. Br. J. Obstet. Gynaecol. 106:1999;706-710.
45. Ngai S.W., Tang O.S., Ho P.C. Randomized comparison of vaginal (200 μg every 3 h) and oral (400 μg every 3 h) misoprostol when combined with mifepristone in termination of second trimester pregnancy. Hum. Reprod. 15:2000;2205-2208.
46. Tang O.S., Thong K.J., Baird D.T. Second trimester medical abortion with mifepristone and gemeprost: a review of 956 cases. Contraception. 64:2001;29-32.
47. Spitz I.M., Bardin C.W. Clinical pharmacology of RU486: an antiprogestin and antiglucocorticoid. Contraception. 48:1993;403-444.
48. Ashok P.W., Kidd A., Flett G.M.M., Fitzmaurice A., Graham W., Templeton A. A randomized comparison of medical abortion and surgical vacuum aspiration at 10-13 weeks gestation. Hum. Reprod. 17:2002;92-98.
49. Gouk E.V., Lincoln K., Khair A., Haslock J., Knight J., Cruickshank D.J. Medical termination of pregnancy at 63-83 days gestation. Br. J. Obstet. Gynaecol. 106:1999;535-539.
50. Hamoda H., Ashok P.W., Flett G.M., Templeton A. Medical abortion at 64 to 91 days of gestation: a review of 483 consecutive cases. Am. J. Obstet. Gynecol. 188:2003;1315-1319.
51. World Health Organization task force on postovulatory methods of fertility regulation. Menstrual regulation by mifepristone plus prostaglandin: results from a multicentre trial. Hum Reprod 1995;10:308-14.
52. Neilson JP, Neilson JP. Mifepristone for induction of labour (Cochrane Review). The Cochrane Library, Issue 1. Oxford: Update Software; 2003.
53. Elliott C.L., Brennand J.E., Calder A.A. The effects of mifepristone on cervical ripening and labor induction in primigravidae. Obstet. Gynecol. 92:1998;804-809.
54. Frydman R., Lelaidier C., Baton Saint Mleux C., Fernandez H., Vial M., Bourget P. Labor induction in women at term with mifepristone (RU486): a double-blind, randomized, placebo-controlled study. Obstet. Gynecol. 80:1992;972-975.
55. Giacalone P.L., Targosz V., Laffargue F., Boog G., Faure J.M. Cervical ripening with mifepristone before labor induction: a randomized study. Obstet. Gynecol. 92:1998;487-492.
56. Lelaidier C., Baton C., Benifla J.L., Fernandez H., Bourget P., Frydman R. Mifepristone for labour induction after previous caesarean section. Br. J. Obstet. Gynaecol. 101:1994;501-503.
57. Stenlund P.M., Ekman G., Aedo A.R., Bygdeman M. Induction of labor with mifepristone: a randomized, double-blind study versus placebo. Acta Obstet. Gynecol. Scand. 78:1999;793-798.
58. Wing D.A., Fassett M.J., Mishell D.R. Mifepristone for preinduction cervical ripening beyond 41 weeks' gestation: a randomized controlled trial. Obstet. Gynecol. 96:2000;543-548.
59. Hill N.C., Selinger M., Ferguson J., MacKenzie I.Z. The placental transfer of mifepristone (RU486) during the second trimester and its influence upon maternal and fetal steroid concentrations. Br. J. Obstet. Gynaecol. 97:1990;406-411.
60. Giacalone P.L., Daures J.P., Faure J.M., Boulot P., Hedon B., Laffargue F. The effects of mifepristone on uterine sensitivity to oxytocin and on fetal heart rate patterns. Eur. J. Obstet. Gynecol. Reprod. Biol. 97:2001;30-34.
61. Lelaidier C., Baton Saint Mleux C., Fernandez H., Bourget P., Frydman R. Mifepristone (RU486) induces embryo expulsion in first trimester non-developing pregnancies: a prospective randomized trial. Hum. Reprod. 8:1993;492-495.
62. Schaff E.A., Fielding S.L., Eisinger S., Stadalius L. Mifepristone and misoprostol for early abortion when no gestational sac is present. Contraception. 63:2001;251-254.
63. Hughes J., Ryan M., Hinshaw K., Henshaw R., Rispin R., Templeton A. The costs of treating miscarriage: a comparison of medical and surgical management. Br. J. Obstet. Gynaecol. 103:1996;1217-1221.
64. El-Rafeay H., Hinshaw K., Henshaw R., Smith N., Templeton A. Medical management of missed abortion and anembryonic pregnancy. BMJ. 305:1992;1399.
65. Wagaarachchi P.T., Ashok P.W., Narvekar N., Smith N.C., Templeton A. Medical management of early fetal demise using a combination of mifepristone and misoprostol. Hum. Reprod. 16:2001;1849-1853.
66. Nielsen S., Hahlin M., Platz Christensen J.J. Unsuccessful treatment of missed abortion with a combination of an antiprogesterone and a prostaglandin E1 analogue. Br. J. Obstet. Gynaecol. 104:1997;1094-1096.
67. Gronlund A., Gronlund L., Clevin L., Andersen B., Palmgren N., Lidegaard O. Management of missed abortion: comparison of medical treatment with either mifepristone + misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen county, Denmark. Acta Obstet. Gynecol. Scand. 81:2002;1060-1065.
68. Nielsen S., Hahlin M. Expectant management of first-trimester spontaneous abortion. Lancet. 345:1995;84-86.
69. Cabrol D., Bouvier D'Yvoire M., Mermet E., Cedard L., Sureau C., Baulieu E.E. Induction of labour with mifepristone after intrauterine fetal death. Lancet. 2:1985;1019.
70. Cabrol D., Dubois C., Cronje H., Gonnet J.M., Guillot M., Maria B.et al. Induction of labor with mifepristone (RU486) in intrauterine fetal death. Am. J. Obstet. Gynecol. 163:1990;540-542.
71. Wagaarachchi P.T., Ashok P.W., Narvekar N.N., Smith N.C., Templeton A. Medical management of late intrauterine death using a combination of mifepristone and misoprostol. BJOG. 109:2002;443-447.
72. Messinis I.E., Krishnan M., Kazem R., Khadilkar S., Templeton A.A. Effect of mifepristone on folliculogenesis in women treated with recombinant FSH. Clin. Endocrinol. Oxf. 46:1997;309-314.
73. Sarkar N.N. The potential of mifepristone (RU486) as a female contraceptive drug. Int. J. Clin. Pract. 56:2002;140-144.
74. Hegele Hartung C., Mootz U., Beier H.M. Luteal control of endometrial receptivity and its modification by progesterone antagonists. Endocrinology. 131:1992;2446-2460.
75. Paulson R.J., Sauer M.V., Lobo R.A. Potential enhancement of endometrial receptivity in cycles using controlled ovarian hyperstimulation with antiprogestins: a hypothesis. Fertil. Steril. 67:1997;321-325.
76. Hodgen G.D., van Uem J.F., Chillik C.F., Danforth D.R., Wolf J.P., Neulen J.et al. Non-competitive anti-oestrogenic activity of progesterone antagonists in primate models. Hum. Reprod. 9(Suppl 1):1994;77-81.
77. Slayden O.D., Zelinski Wooten M.B., Chwalisz K., Stouffer R.L., Brenner R.M. Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. Hum. Reprod. 13:1998;269-277.
78. Slayden O.D., Brenner R.M. RU486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (Macaca mulatta). J. Clin. Endocrinol. Metab. 78:1994;440-448.
79. Baird D.T., Brown A., Critchley H.O., Williams A.R., Lin S., Cheng L. Effect of long-term treatment with low-dose mifepristone on the endometrium. Hum. Reprod. 18:2003;61-68.
80. Grow D.R., Williams R.F., Hsiu J.G., Hodgen G.D. Antiprogestin and/or gonadotropin-releasing hormone agonist for endometriosis treatment and bone maintenance: a 1-year primate study. J. Clin. Endocrinol. Metab. 81:1996;1933-1939.
81. McDonnell D.P., Goldman M.E. RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. J. Biol. Chem. 269:1994;11945-11949.
82. Zelinski Wooten M.B., Slayden O.D., Chwalisz K., Hess D.L., Brenner R.M., Stouffer R.L. Chronic treatment of female rhesus monkeys with low doses of the antiprogestin ZK 137 316: establishment of a regimen that permits normal menstrual cyclicity. Hum. Reprod. 13:1998;259-267.
83. Chwalisz K., Brenner R.M., Fuhrmann U.U., Hess Stumpp H., Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids. 65:2000;741-751.
84. Koji T., Chedid M., Rubin J.S., Slayden O.D., Csaky K.G., Aaronson S.A. et al. Progesterone-dependent expression of keratinocyte growth factor mRNA in stromal cells of the primate endometrium: keratinocyte growth factor as a progestomedin. J. Cell Biol. 125:1994;393-401.
85. Grow D.R., Reece M.T., Hsiu J.G., Adams L., Newcomb P.M., Williams R.F. et al. Chronic antiprogestin therapy produces a stable atrophic endometrium with decreased fibroblast growth factor: a 1-year primate study on contraception and amenorrhea. Fertil. Steril. 69:1998;936-943.
86. Greb R.R., Heikinheimo O., Williams R.F., Hodgen G.D., Goodman A.L. Vascular endothelial growth factor in primate endometrium is regulated by oestrogen-receptor and progesterone-receptor ligands in vivo. Hum. Reprod. 12:1997;1280-1292.
87. Heikinheimo O., Hsiu J.G., Gordon K., Kim S., Williams R.F., Gibbons W.E.et al. Endometrial effects of RU486 in primates: antiproliferative action despite signs of estrogen action and increased cyclin-B expression. J. Steroid Biochem. Mol. Biol. 59:1996;179-190.
88. Parthasarathy S., Morales A.J., Murphy A.A. Antioxidant: a new role for RU486 and related compounds. J. Clin. Invest. 94:1994;1990-1995.
89. Neulen J., Williams R.F., Breckwoldt M., Chwalisz K., Baulieu E.E., Hodgen G.D. Non-competitive anti-oestrogenic actions of progesterone antagonists in primate endometrium: enhancement of oestrogen and progesterone receptors with blockade of postreceptor proliferative mechanisms. Hum. Reprod. 11:1996;1533-1537.
90. Brenner R.M., Slayden O.D., Critchley H.O. Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction. 124:2002;167-172.
91. Slayden O.D., Brenner R.M. Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium. J. Clin. Endocrinol. Metab. 88:2003;946-949.
92. Englund K., Blanck A., Gustavsson I., Lundkvist U., Sjoblom P., Norgren A.et al. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and gonadotropin-releasing hormone treatment. J. Clin. Endocrinol. Metab. 83:1998;4092-4096.
93. Brandon D.D., Bethea C.L., Strawn E.Y., Novy M.J., Burry K.A., Harrington M.S.et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am. J. Obstet. Gynecol. 169:1993;78-85.
94. Yen SSC. Use of antiprogestins in the management of endometriosis and leiomyoma. In: Donaldson MS, Dorflinger L, Brown SS, Benet LZ, editors. Clinical applications of mifepristone (RU496) and other antiprogestins. Washington, DC: National Academy Press; 1993. p. 189-209.
95. Murphy A.A., Castellano P.Z. RU486: pharmacology and potential use in the treatment of endometriosis and leiomyomata uteri. Curr. Opin. Obstet. Gynecol. 6:1994;269-278.
96. Yang Y., Zheng S., Li K. Treatment of uterine leimyoma by two different doses of mifepristone. Chin. J. Obstet. Gynecol. 31:1996;624-626.
97. Eisinger S.H., Meldrum S., Fiscella K., le Roux H.D., Guzick D.S. Low-dose mifepristone for uterine leiomyomata. Obstet. Gynecol. 101:2003;243-250.
98. Zeng C., Gu M., Huang H. A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone. Zhonghua Fu Chan Ke Za Zhi. 33:1998;490-492.
99. Chwalisz K., Parker L., Williamson S. Treatment of uterine leiomyomas with the novel selective progesterone receptor modulator (SPRM). J. Soc. Gynecol. Investig. 10:2003;301A.
100. Kettel L.M., Murphy A.A., Morales A.J., Rivier J., Vale W., Yen S.S. Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil. Steril. 60:1993;642-646.
101. Kettel L.M., Murphy A.A., Morales A.J., Ulmann A., Baulieu E.E., Yen S.S. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil. Steril. 65:1996;23-28.
102. Kettel L.M., Murphy A.A., Morales A.J., Yen S.S. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU486). Am. J. Obstet. Gynecol. 178:1998;1151-1156.
103. Han S., Sidell N. RU486-induced growth inhibition of human endometrial cells involves the nuclear factor-kappa B signaling pathway. J. Clin. Endocrinol. Metab. 88:2003;713-719.
104. Nieman L.K., Chrousos G.P., Kellner C., Spitz I.M., Nisula B.C., Cutler G.B.et al. Successful treatment of Cushing's syndrome with the glucocorticoid antagonist RU486. J. Clin. Endocrinol. Metab. 61:1985;536-540.
105. Chu J.W., Matthias D.F., Belanoff J., Schatzberg A., Hoffman A.R., Feldman D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU486). J. Clin. Endocrinol. Metab. 86:2001;3568-3573.
106. Spitz I.M., Bardin C.W. Mifepristone (RU486): a modulator of progestin and glucocorticoid action. N. Engl. J. Med. 329:1993;404-412.
107. Mirani M., Elenkov I., Volpi S., Hiroi N., Chrousos G.P., Kino T. HIV-1 protein Vpr suppresses IL-12 production from human monocytes by enhancing glucocorticoid action: potential implications of Vpr coactivator activity for the innate and cellular immunity deficits observed in HIV-1 infection. J. Immunol. 169:2002;6361-6368.
108. McEwen B.S., Davis P.G., Parsons B., Pfaff D.W. The brain as a target for steroid hormone action. Annu. Rev. Neurosci. 2:1979;65-112.
109. Pomara N., Doraiswamy P.M., Tun H., Ferris S. Mifepristone (RU486) for Alzheimer's disease. Neurology. 58:2002;1436.
110. Belanoff J.K., Jurik J., Schatzberg L.D., DeBattista C., Schatzberg A.F. Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. J. Mol. Neurosci. 19:2002;201-206.
111. Belanoff J.K., Rothschild A.J., Cassidy F., DeBattista C., Baulieu E.E., Schold C.et al. An open label trial of C-1073 (mifepristone) for psychotic major depression. Biol. Psychiatr. 52:2002;386-392.
112. Belanoff J.K., Flores B.H., Kalezhan M., Sund B., Schatzberg A.F. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 21:2001;516-521.
113. Pearson Murphy B.E. Antiglucocorticoid therapies in major depression: a review. Psychoneuroendocrinology. 22(Suppl 1):1997;S125-S132.
114. Klijn J.G., Setyono Han B., Foekens J.A. Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer. Steroids. 65:2000;825-830.
115. Romieu G., Maudelonde T., Ulmann A., Pujol H., Grenier J., Cavalie G.et al. The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer. 74:1987;455-461.
116. Perrault D., Eisenhauer E.A., Pritchard K.I., Panasci L., Norris B., Vandenberg T.et al. Phase II study of the progesterone antagonist mifepristone in patients with untreated metastatic breast carcinoma: a National Cancer Institute of Canada Clinical Trials Group Study. J. Clin. Oncol. 14:1996;2709-2712.
117. Bakker G.H., Setyono Han B., Portengen H., De Jong F.H., Foekens J.A., Klijn J.G. Treatment of breast cancer with different antiprogestins: preclinical and clinical studies. J. Steroid Biochem. Mol. Biol. 37:1990;789-794.
118. Grunberg S.M., Weiss M.H., Spitz I.M., Ahamadi J., Sadun A., Russell C.A.et al. Treatment of unresecatable meningiomas with the antipprogesterone agent mifepristone. J. Neurosurg. 74:1991;861-864.
119. Grunberg S.M. Role of antiprogestational therapy for meningiomas. Hum. Reprod. 9(Suppl 1):1994;202-207.
120. Grunberg SM, Rankin C, Townsend J, Ahamadi J, Feun L, Fredricks R, et al. Phase III double-blind randomized placebo-controlled study of mifepristone (RU) for the treatment of unresectable meningioma. San Francisco, CA. Am Soc Clin Oncol 2001;20.
121. Rocereto T.F., Saul H.M., Aikins J.A. Jr., Paulson J. Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol. Oncol. 77:2000;429-432.
122. UK Multicenter Study Group. Oral mifepristone 600 mg and vaginal gemeprost for mid-trimester induction of abortion. An open multicenter study. Contraception 1997;56:361-6.
123. Phillips K., Berry C., Mathers A.M. Uterine rupture during second trimester termination of pregnancy using mifepristone and a prostaglandin. Eur. J. Obstet. Gynecol. Reprod. Biol. 65:1996;175-176.
124. Norman J.E. Uterine rupture during therapeutic abortion in the second trimester using mifepristone and prostaglandin. Br. J. Obstet. Gynaecol. 102:1995;332-333.
125. Sinave C., Le Templier G., Blouin D., Leveille F., Deland E. Toxic shock syndrome due to Clostridium sordellii: a dramatic postpartum and postabortion disease. Clin. Infect. Dis. 35:2002;1441-1443.
126. Gonzalez C.H., Marques Dias M.J., Kim C.A., Sugayama S.M., Da Paz J.A., Huson S.M.et al. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet. 351:1998;1624-1627.
127. Gonzalez C.H., Vargas F.R., Perez A.B., Kim C.A., Brunoni D., Marques Dias M.J.et al. Limb deficiency with or without Mobius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am. J. Med. Genet. 47:1993;59-64.
128. Fonseca W., Alencar A.J., Mota F.S., Coelho H.L. Misoprostol and congenital malformations. Lancet. 338:1991;56.
129. Pastuszak A.L., Schuler L., Speck Martins C.E., Coelho K.E., Cordello S.M., Vargas F.et al. Use of misoprostol during pregnancy and Mobius syndrome in infants. N. Engl. J. Med. 338:1998;1881-1885.
130. Lamberts S.W., Koper J.W., de Jong F.H. The endocrine effects of long-term treatment with mifepristone (RU486). J. Clin. Endocrinol. Metab. 73:1991;187-191.
131. Heikinheimo O., Ranta S., Grunberg S., Lahteenmaki P., Spitz I.M. Alterations in the pituitary-thyroid and pituitary-adrenal axes - consequences of long-term mifepristone treatment. Metabolism. 46:1997;292-296.
132. Takiyama Y., Tanaka H., Makino I. The effects of hydrocortisone and RU486 (mifepristone) on iodide uptake in porcine thyroid cells in primary culture. Endocrinology. 135:1994;1972-1979.
133. Cameron S.T., Thong K.J., Baird D.T. Effect of daily low dose mifepristone on the ovarian cycle and on dynamics of follicle growth. Clin. Endocrinol. Oxf. 43:1995;407-414.
134. Murphy A.A., Morales A.J., Kettel L.M., Yen S.S. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil. Steril. 64:1995;187-190.
135. Murphy A.A., Kettel L.M., Morales A.J., Roberts V.J., Yen S.S. Regression of uterine leiomyomata in response to the antiprogesterone RU486. J. Clin. Endocrinol. Metab. 76:1993;513-517.
136. Eisinger S.H., Meldrum S., Fiscella K., le Roux H.D., Guzick D.S. Low-dose mifepristone for uterine leiomyomata. Obstet. Gynecol. 101:2003;243-250.
137. Laue L., Lotze M.T., Chrousos G.P., Barnes K., Loriaux D.L., Fleisher T.A. Effect of chronic treatment with the glucocorticoid antagonist RU486 in man: toxicity, immunological, and hormonal aspects. J. Clin. Endocrinol. Metab. 71:1990;1474-1480.
138. Chwalisz K., Stockemann K., Fritzemeier K.H., Fuhrmann U. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus. Hum. Reprod. Update. 4:1998;570-583.
139. Rumpel E., Michna H., Kuhnel W. Morphology of the rat uterus after long-term treatment with progesterone antagonists. Anat. Anz. 175:1993;141-149.
140. Bigsby R.M., Young P.C. Estrogenic effects of the antiprogestin onapristone (ZK98.299) in the rodent uterus. Am. J. Obstet. Gynecol. 171:1994;188-194.
141. Newfield R.S., Spitz I.M., Isacson C., New M.I. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin. Endocrinol. Oxf. 54:2001;399-404.
142. Martineau P.A., Levental M. Large endometrial polyp in a patient on long-term mifepristone therapy. J. Ultrasound Med. 19:2000;487-489.
143. Murphy A.A., Kettel L.M., Morales A.J., Roberts V., Parmley T., Yen S.S. Endometrial effects of long-term low-dose administration of RU486. Fertil. Steril. 63:1995;761-766.
144. Croxatto H.B., Kovacs L., Massai R., Resch B.A., Fuentealba B., Salvatierra A.M.et al. Effects of long-term low-dose mifepristone on reproductive function in women. Hum. Reprod. 13:1998;793-798.
145. Heikinheimo O., Ranta S., Grunberg S., Spitz I.M. Alterations in sex steroids and gonadotropins in postmenopausal women subsequent to long-term mifepristone administration. Steroids. 65:2000;831-836.
146. Schmidt M., Loffler G. RU486 is a potent inhibitor of aromatase induction in human breast adipose tissue stromal cells. J. Steroid Biochem. Mol. Biol. 60:1997;197-204.
147. Tseng L., Mazella J., Sun B. Modulation of aromatase activity in human endometrial stromal cells by steroids. Endocrinology. 118:1986;1312-1318.
148. Croxatto H.B., Salvatierra A.M., Croxatto H.D., Fuentealba B. Effects of continuous treatment with low dose mifepristone throughout one menstrual cycle. Hum. Reprod. 8:1993;201-207.
149. Weihua Z., Saji S., Makinen S., Cheng G., Jensen E.V., Warner M. Estrogen receptor (ER) beta, a modulator of ERalpha in the uterus. Proc. Natl. Acad. Sci. U.S.A. 97:2000;5936-5941.
150. Hall J.M., McDonnell D.P. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology. 140:1999;5566-5578.
151. Zou A., Marschke K.B., Arnold K.E., Berger E.M., Fitzgerald P., Mais D.E.et al. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen. Mol. Endocrinol. 13:1999;418-430.
152. Mulac-Jericevic B., Mullinax R.A., DeMayo F.J., Lydon J.P., Conneely O.M. Subgroup of reproductive functions of progesterone mediated by progesterone receptor-B isoform. Science. 289:2000;1751-1754.